Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Quizartinib for the treatment of acute myeloid leukemia.

Expert opinion on pharmacotherapy - 1 Dec 2020

Garcia-Horton Alejandro, Yee Karen Wl

Abstract excerpt

INTRODUCTION: . Up to 30% of patients with acute myeloid leukemia (AML) have a mutation in the FLT3 receptor. Molecular targets have acquired a significant interest in the treatment of AML and are changing patient outcomes, including improvement of overall survival (OS) and remission rates. FLT3 inhibitors have obtained a central role in how we treat AML. AREAS COVERED: . This article reviews the mechanism of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzothiazoles
Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Remission Induction

Share to Treatment Outcome

Source

Identifiers

PMID: 32772726
DOI: 10.1080/14656566.2020.1801637

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Quizartinib for the treatment of acute myeloid leukemia.PMID 32772726Read ↗

The role of quizartinib in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Semantic proximity Read ↗

Quizartinib: a potent and selective FLT3 inhibitor for the treatment of patients with FLT3-ITD-positive AML.Semantic proximity Read ↗

Management and risk mitigation strategies for FLT3-ITD+ acute myeloid leukemia: clinical utilization of quizartinib.Semantic proximity Read ↗

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.Semantic proximity Read ↗

Safety of FLT3 inhibitors in patients with acute myeloid leukemia.Semantic proximity Read ↗

Emerging FLT3 inhibitors for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

FLT3 Inhibitors for Treating Acute Myeloid Leukemia.Semantic proximity Read ↗

Advances in clinical studies of FLT3 inhibitors in acute myeloid leukemia.Semantic proximity Read ↗

Practical Considerations for Treatment of Relapsed/Refractory FLT3-ITD Acute Myeloid Leukaemia with Quizartinib: Illustrative Case Reports.Semantic proximity Read ↗

FLT3-targeted treatment for acute myeloid leukemia.Semantic proximity Read ↗

FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.